Dopamine Receptors and Their Heteroreceptor Complexes Give Novel Targets for Drug Development

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 242

Special Issue Editors

Instituto de Fisiologia Celular de la UNAM, Mexico City, Mexico
Interests: neuroanatomy; neuroscience; cognitive neuroscience; neurobiology; neurobiology and brain physiology; neuropharmacology; behavioral neuroscience; electrophysiology; neurophysiology; neurodegeneration
Department of Neuroscience, Karolinska Institutet; Retzius väg 8, 17177 Stockholm, Sweden
Interests: neuropharmacology; behavioral neuroscience; neurobiology; neurobiology and brain physiology; neurodegeneration; neurodegenerative diseases; immunohistochemistry; cellular neuroscience; neuroscience; neuroimaging
Special Issues, Collections and Topics in MDPI journals
Karolinska Inst., Dept Neurosci., Stockholm, Sweden
Interests: neuroscience; biochemistry; molecular biology; bioinformatics and computational biology; cell signaling; cell culture; neurobiology; neurodegenerative diseases; PCR; immunohistochemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Disturbances in dopamine (DA) receptor subtypes D1, D2, D3, and D4 have been shown to play a significant or crucial role in the pathophysiology of Parkinson’s disease, schizophrenia, cocaine addiction, and other diseases. The therapeutic effects of levodopa and dopamine agonists have been significant but nevertheless considerably limited in Parkinson’s disease, which is true also for the treatment of schizophrenia with D2R antagonists. The number of side effects is also substantial, which furthermore limits their use in neurology and psychiatry. However, the discovery of a considerable number of DA heteroreceptor complexes in the forebrain, such as A2AR-D2R heterocomplexes—in which allosteric receptor–receptor interactions exist to modulate the function of the D2R protomers—open the possibility to enhance or reduce the D2R signaling at the postsynaptic or extra-synaptic level. Likewise, at the presynaptic level, the modulation of the D2R protomer in the A2AR-DR complex can enhance or reduce the release of neurotransmitters such as glutamate. DAR-protein heterocomplexes also exist presynaptically and play a significant role. These mechanisms operating in DA heteroreceptor complexes provide a novel way to improve the treatment of the neurological and mental diseases herein discussed, including a reduction in the side effects.

Dr. Miguel Pérez-de la Mora
Prof. Dr. Kjell Fuxe
Dr. Dasiel O. Borroto-Escuela
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dopamine
  • dopamine receptors
  • receptor oligomerization
  • Parkinson’s disease
  • schizophrenia
  • anxiety
  • depression
  • drug addiction

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop